학술논문
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)
Document Type
Article
Author
Source
In Journal of the American Academy of Dermatology September 2023 89(3):478-485
Subject
Language
ISSN
0190-9622